Tempus AI shares climbed approximately 35.5% over the last 30 days, including a significant surge this week. A technical short squeeze further amplified the stock's upward momentum.
The company expanded its AI-driven precision-medicine partnership with Merck. H.C. Wainwright subsequently increased its price target on the stock to $66 from $56, citing confidence in the company's growth trajectory.
The FDA recently granted 510(k) clearance for AI-enabled software that detects signs of pulmonary hypertension. Additionally, the company secured up to $9.5 million in funding from ARPA-H to develop autonomous AI in cardiology.
Revenue grew 22% year-over-year according to the second-quarter 2026 earnings report. The company also achieved positive net income during this period.